The scientist’s investigation covers issues in Cannabis, Psychiatry, Cannabidiol, Dronabinol and Demography. Tom P. Freeman has researched Cannabis in several fields, including Psychosis, Odds and Substance abuse. As a part of the same scientific family, Tom P. Freeman mostly works in the field of Psychiatry, focusing on Recall and, on occasion, Schizophrenia.
His Cannabidiol research includes themes of Tetrahydrocannabinol, Drug and Delta-9-tetrahydrocannabinol. Tom P. Freeman connects Demography with Potency in his research. His work deals with themes such as Major depressive disorder, Apathy and Clinical psychology, which intersect with Addiction.
His main research concerns Cannabis, Psychiatry, Cannabidiol, Clinical psychology and Addiction. His Tetrahydrocannabinol research extends to the thematically linked field of Cannabis. Psychiatry and Young adult are frequently intertwined in his study.
His study in Cannabidiol is interdisciplinary in nature, drawing from both Dronabinol, Cannabis Dependence, Delta-9-tetrahydrocannabinol and Pharmacology. As part of one scientific family, Tom P. Freeman deals mainly with the area of Clinical psychology, narrowing it down to issues related to the Dopaminergic, and often Psychosocial stress. His study in the field of Craving also crosses realms of Pramipexole.
Tom P. Freeman mainly investigates Cannabis, Psychiatry, Cannabidiol, Anxiety and Injury prevention. His Cannabis research is multidisciplinary, relying on both Psychosis and Tetrahydrocannabinol. His study involves Mental health, Addiction, Hashish and Substance abuse, a branch of Psychiatry.
His work in Addiction addresses subjects such as Nicotine, which are connected to disciplines such as Functional magnetic resonance imaging. The study incorporates disciplines such as Placebo, Hippocampus and Cannabis use disorder in addition to Cannabidiol. His Anxiety study combines topics in areas such as Dual diagnosis and Clinical psychology.
Cannabis, Psychiatry, Addiction, Cannabidiol and Cannabis use are his primary areas of study. The concepts of his Cannabis study are interwoven with issues in Mental health and Psychopathology. His work in the fields of Psychiatry, such as Hashish, Nicotine and Psychosis, intersects with other areas such as Brain activity and meditation.
The various areas that Tom P. Freeman examines in his Addiction study include Middle temporal gyrus, Functional magnetic resonance imaging, Ventromedial prefrontal cortex and Neuroeconomics. His research integrates issues of Pharmacology, Craving and Environmental health in his study of Cannabidiol. Cannabis use is closely attributed to Tetrahydrocannabinol in his research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study
Marta Di Forti;Marta Di Forti;Marta Di Forti;Diego Quattrone;Diego Quattrone;Diego Quattrone;Tom P. Freeman;Giada Tripoli.
The Lancet Psychiatry (2019)
Keep off the grass? Cannabis, cognition and addiction
H. Valerie Curran;Tom P. Freeman;Claire Mokrysz;David A. Lewis.
Nature Reviews Neuroscience (2016)
Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study
Celia J A Morgan;Gráinne Schafer;Tom P Freeman;H Valerie Curran.
British Journal of Psychiatry (2010)
New trends in cannabis potency in USA and Europe during the last decade (2008-2017).
Suman Chandra;Mohamed M Radwan;Chandrani G Majumdar;James C Church.
European Archives of Psychiatry and Clinical Neuroscience (2019)
Examining the profile of high-potency cannabis and its association with severity of cannabis dependence.
T. P. Freeman;Adam Winstock.
Psychological Medicine (2015)
Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.
Celia J A Morgan;Tom P Freeman;Gráinne L Schafer;H Valerie Curran.
Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.
C.J.A. Morgan;C. Gardener;G. Schafer;S. Swan.
Psychological Medicine (2012)
The neuropsychopharmacology of cannabis: a review of human imaging studies
Michael A.P. Bloomfield;Chandni Hindocha;Sebastian F. Green;Matthew B. Wall.
Pharmacology & Therapeutics (2019)
Medicinal use of cannabis based products and cannabinoids
Tom P Freeman;Chandni Hindocha;Chandni Hindocha;Sebastian F Green;Michael A P Bloomfield.
Can we make cannabis safer
Amir Englund;Tom P Freeman;Robin M Murray;Philip McGuire.
The Lancet Psychiatry (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: